A2A antagonists were found not to be prodyskinetic drugs, since their administration to Parkinsonian primates with established dyskinesia induced by L-DOPA relieved motor impairment and did not worsen dyskinesia [22–24]. This evidence concerns the gene IGKV2D-29 and Dyskinesia.